title: Tolvaptan (Otsuka).
abstract: Otsuka is developing tolvaptan (OPC-41061), an orally active non-peptide vasopressin V2 antagonist, as a diuretic for the potential treatment of congestive heart failure. By November 2003, tolvaptan was undergoing phase III clinical trials.
authors.affiliation: Doggrell Biomedical Communications, 47 Caronia Crescent, Lynfield, Auckland, New Zealand. s.doggrell@xtra.co.nz
authors.forename: Sheila A
authors.initials: SA
authors.lastname: Doggrell
mesh_terms: D000818:Animals; D065092:Antidiuretic Hormone Receptor Antagonists; D001552:Benzazepines / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004232:Diuretics / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D006333:Heart Failure / Q000188:drug therapy; D006801:Humans; D017483:Receptors, Vasopressin / Q000378:metabolism; D013329:Structure-Activity Relationship; D000077602:Tolvaptan
chemical_list: D065092:Antidiuretic Hormone Receptor Antagonists; D001552:Benzazepines; D004232:Diuretics; D017483:Receptors, Vasopressin; D000077602:Tolvaptan